Clinical trials
Hypercholesterolemia trials in Russia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 6 |
| 2014 | 2 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sanofi | 11 |
| Amgen | 9 |
| Kowa Research Europe | 3 |
| Takeda | 3 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2 |
| Regeneron Pharmaceuticals | 2 |
| AtheroNova Inc. | 1 |
| Kastle Therapeutics, LLC | 1 |
| National Medical Research Center for Rehabilitation and Balneology | 1 |
| National Medical Research Center for Therapy and Preventive Medicine | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hypercholesterolemia | 36 |
| Dyslipidemias | 9 |
| Hyperlipidemias | 8 |
| Hyperlipoproteinemia Type II | 3 |
| Atherosclerosis | 2 |
| Coronary Artery Disease | 2 |
| Homozygous Familial Hypercholesterolemia | 2 |
| Cardiovascular Diseases | 1 |
| Diabetes Mellitus | 1 |
| Gout | 1 |
Trials
Showing 26 to 36 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.